TL;DR
The United States has stopped funding Gavi, the global vaccine alliance, over disagreements about vaccine ingredients and policies. This move threatens to undermine immunization efforts in poorer countries, risking increased disease outbreaks and deaths.
The United States is currently withholding nearly $600 million in funding from Gavi, the global vaccine alliance, threatening to disrupt immunization programs in low-income countries. This decision stems from political disputes over vaccine ingredients and safety concerns, and it risks reversing years of progress in global health efforts.
Since 2024, the U.S. has withheld a significant portion of its pledged funding to Gavi, which is responsible for immunizing millions in developing countries. The withholding follows accusations by U.S. officials, including Health Secretary Robert F. Kennedy Jr., that Gavi has ignored scientific evidence and relied on vaccines containing thimerosal, a preservative Kennedy claims causes harm—claims that lack supporting data. Despite Gavi’s continued endorsement of the efficacy of older vaccines like the diphtheria-tetanus-pertussis (DTwP) shot, the U.S. government has demanded changes to its vaccination strategy, including halting the use of thimerosal-containing vaccines. The U.S. government’s actions have led to delays in disbursing funds authorized by Congress, risking the continuation of vaccination campaigns in vulnerable populations.
Officials from the State Department and the Department of Health and Human Services have indicated ongoing discussions with Gavi, but no resolution has been reached. Experts warn that halting the use of affordable, long-proven vaccines like DTwP in low-resource settings could lead to increased disease transmission and preventable deaths, reversing decades of progress in global health.
Why It Matters
This development highlights how political and ideological disputes in the U.S. are impacting global health initiatives. The withholding of funds threatens to undo years of progress in reducing childhood mortality from preventable diseases in impoverished regions. It also risks eroding international trust in U.S. commitments to global health, potentially weakening future cooperation and funding for immunization efforts worldwide.
The Ultimate Vaccine Timeline: A Fact-Packed History of Vaccines and Their Makers
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Gavi, founded in 2000, has played a vital role in increasing vaccine access in low-income countries, supported by major donors including the U.S., which pledged nearly $1.6 billion in 2024. Historically, U.S. contributions have covered roughly 13% of Gavi’s funding through 2030. Recent political shifts and vaccine skepticism, particularly under the influence of Kennedy and some factions of the Trump administration, have led to the suspension of U.S. payments. The dispute centers around vaccine ingredients like thimerosal and the safety of certain formulations, despite global health authorities like WHO reaffirming their safety and efficacy. The U.S. has also questioned Gavi’s policies on vaccine safety, demanding changes that could limit access to affordable vaccines in resource-limited settings.
““President Trump entrusted Secretary Robert F. Kennedy Jr. to manage the U.S. government’s relationship with Gavi,””
— A U.S. State Department spokesperson
““Using cheaper vaccines like DTwP is essential in low-resource settings because they are more effective long-term and require fewer doses, which is critical for access and compliance,””
— Seth Berkley, infectious disease expert and former Gavi CEO
““We are cautiously optimistic that ongoing discussions could lead to a constructive path forward,””
— A U.S. official from HHS
thimerosal-free childhood vaccines
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear when the U.S. will release the withheld funds or if Gavi will alter its vaccine policies as demanded. The full impact of the funding suspension on ongoing immunization campaigns is still emerging, and international health experts warn that delays could lead to increased disease outbreaks. The precise scope of political influence over U.S. health policy in this context is also still being evaluated.
affordable vaccines for low-resource settings
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include continued negotiations between U.S. officials and Gavi, with potential for partial funding releases if agreements are reached. Monitoring the impact on vaccination campaigns in low-income countries over the coming months will be critical. International organizations are also likely to seek alternative funding sources to mitigate disruptions.
International Certificate of Vaccination or Prophylaxis
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Why is the U.S. withholding funds from Gavi?
The U.S. cites concerns over vaccine ingredients, safety, and Gavi’s policies, particularly regarding thimerosal and vaccine formulations, as reasons for withholding funds. These claims are disputed by global health authorities.
What could be the impact of this funding halt?
Disruptions to vaccination programs in low-income countries could lead to increased outbreaks of preventable diseases, higher child mortality, and setbacks in global health progress.
Is this issue only about vaccine safety?
No. While vaccine safety is a concern cited by U.S. officials, experts emphasize that the core issue involves access to affordable, proven vaccines and the political disputes influencing funding decisions.
Could this affect U.S. global health commitments?
Yes. The withholding of funds may undermine U.S. credibility and influence in international health initiatives, potentially affecting future cooperation and funding commitments.
What is likely to happen next?
Negotiations will continue, with possible partial releases of funds if agreements are reached. The global health community will closely monitor vaccination efforts and disease trends in affected regions.
Source: The Atlantic
